NCT02239172已完成1 期
A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults
Fraunhofer, Center for Molecular Biotechnology2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2014年8月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Number of Participants with Adverse Events
研究概览
简要总结
The purposes of this study is to evaluate and compare the safety, reactogenicity, and tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Citizen or permanent resident of the US
- •Male or female aged 18 to 49 years inclusive
- •Able to give written informed consent
- •Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examinations at baseline
- •Females should fulfill one of the following criteria:
- •At least one year post-menopausal
- •Surgically sterile
- •Willing to use a medically approved form of contraception (eg, oral, implantable, transdermal, or injectable hormonal contraceptive; intrauterine device; barrier protection to include female condom, diaphragm, cervical cap, or male condoms in conjunction with spermicide) for 30 days prior to first vaccination and through the end of the study
- •Willing to abstain from sexual intercourse for 30 days prior to first vaccination and through the end of the study
- •Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of each dose
- •Comprehension of the study requirements
- •Expressed availability for the required study period
- •Ability to attend scheduled visits and to be contacted by telephone throughout the follow-up period
排除标准
- •History of anthrax disease or receipt of anthrax vaccine
- •Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical or surgical treatment or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening
- •Positive serology for HIV-1 or HIV-2, or HBsAg or HCV antibodies
- •Pregnancy or lactation
- •Cancer or treatment for cancer, within the previous 3 years, excluding basal cell carcinoma
- •Presence of any medical condition that may be associated with impaired immune responsiveness, including diabetes mellitus, per the investigator's discretion
- •Presently receiving or history of receiving, during the preceding 3-month period, any medications or other treatments that may adversely affect the immune system
- •This includes allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids (oral or injectable; 20 mg/day x 14 days or longer)
- •Radiation therapy
- •Intranasal and topical corticosteroids will be allowed
- •Receipt or planned administration of a non study vaccine within 14 days prior to vaccination and throughout the study period (30 days for live vaccines) Immunization on an emergency basis with Tetanus Toxoids Adsorbed for adult use (Td or Tdap) or influenza vaccine up to 14 days before or at least 14 days after a dose of study vaccine will be allowed
- •History of anaphylactic type reaction to injected vaccines
- •History of drug or chemical abuse in the year before the study
- •Receipt of any investigational product or nonregistered drug within 30 days prior to vaccination or currently enrolled in any investigational drug study or intends to enroll in such a study within the ensuing study period
- •Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the study period
- •Donation of blood or blood products within 8 weeks prior to vaccination or at any time during the study
- •Acute disease within 72 hours prior to vaccination
- •Acute disease is defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical examination) with or without fever (≥38°C; 100.4°F), or an oral temperature of ≥38°C orally
- •Study vaccine can be administered to persons with a minor illness
- •History of immunodeficiency, chronic illness requiring continuous or frequent medical intervention, autoimmune disease, use of immunosuppressive medications, or ongoing therapy with systemic corticosteroids within 3 months prior to any planned vaccine dose. Inhaled and topical steroids are permitted. "Burst" therapy of steroids is permitted except within 2 weeks prior to vaccination.
- •Evidence of psychiatric, medical and/or substance abuse problems during the past 6 months that the investigator believes would adversely affect the subject's ability to participate in the trial
- •Occupational or other responsibilities that would prevent completion of participation in the trial, including:
- •US military or reservists who may receive the licensed anthrax vaccine (BioThrax) or served during the Persian Gulf War between January and May,
- •Such individuals may be enrolled only if they provide their medical records, which can then show proof that they have not received the licensed anthrax vaccine.
- •Postal and other workers who may be exposed to anthrax or may have to take BioThrax
- •Any condition that, in the opinion of the investigator, might interfere with interpretation of data supporting the primary study objectives
结局指标
主要结局
Number of Participants with Adverse Events
时间窗: Up to 3 months
次要结局
- Change from Baseline in antibody titer after three immunizations(Up to 6 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve AdultsZika VirusNCT03611946National Institute of Allergy and Infectious Diseases (NIAID)56
已完成
1 期
Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy SubjectsSmallpoxNCT00189943Bavarian Nordic90
已完成
1 期
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVacInfluenza A Virus InfectionInfluenza EpidemicInfluenza AInfluenza H5N1NCT03651544Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation36
已完成
1 期
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult ParticipantsHealthy VolunteerNCT06774313AbbVie73
已完成
1 期
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 DiabetesDiabetes Mellitus, Type 1NCT02038764Pfizer37